Pediatric Enhanced Surveillance Study
NCT02043769
Acquired Immune Deficiency Syndrome (AIDS), Acquired Immunodeficiency Syndrome
East London, Amathole, South Africa
View Trial DetailsNCT Number: NCT01997346
The availability of HIV care and treatment programs is increasing in sub-Saharan Africa. However more than half the patients who need HIV medicines are still not receiving this antiretroviral therapy (ART), and this can lead to early death from AIDS. One of the problems in this region is that patients start ART late, after the HIV disease is very advanced. This results in high death rates soon after ART initiation. The way clinic-level factors, such as the way services and referrals are organized, how referrals are regarded, counseling messages and record-keeping, contribute to late ART initiation is unclear. As the second phase of a 3-phase NIH-sponsored project, this study will identify clinic-level enablers and barriers to timely enrollment into HIV care and ART initiation. A cross-sectional qualitative study will be conducted at 4 selected HIV care and treatment clinics and the health facilities in which they are located in Ethiopia. Data will be collected using 4 methods:
1. Data abstraction 2. Key informant interviews with clinic personnel 3. Observation of post-test counseling sessions in the VCT clinic 4. Observation of provider-patient interactions in the care and treatment clinic Identifying modifiable health facility-level predictors of late ART initiation will facilitate implementation of interventions, programs and policies that will increase the number of patients who enroll in HIV care and initiate ART early. Additionally, results will inform the design of the third phase of the NIH-project referenced above.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Fitche Hospital, Fichē, Ethiopia
Background: Although HIV care and treatment programs are scaling up in sub-Saharan Africa, more than 50% of patients who need ART are not receiving it and significant mortality from AIDS persists. One major challenge in this region is high rates of late ART initiation (i.e., in the advanced stages of HIV disease) which results in high rates of mortality soon after ART initiation. The clinic-level factors that contribute to late ART initiation are unclear.
Objective: As the second of a 3-phase NIH-sponsored project, this study aims to identify clinic-level enablers and barriers to timely ART initiation.
Methods: A cross-sectional qualitative study will be conducted at 4 purposively selected HIV care and treatment clinics in Ethiopia. Data will be collected using 4 methods:
Expected use of results: Identifying modifiable clinic-level enablers and barriers to timely ART initiation will facilitate implementation of interventions, programs and policies to reduce late ART initiation. Additionally, results will inform the third phase of the NIH-project referenced above.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
The inclusion and exclusion criteria for the clinics and the various study participants are given below:
Inclusion criteria
N/A - all study sites included. Exclusion criteria: N/A - all study sites included. .
Inclusion criteria
Exclusion criteria
Inclusion criteria
Exclusion criteria
Inclusion criteria
Exclusion criteria
Time frame: 12 months
Visit type includes post-test counseling, enrollment, 1st CD4, pre-ART monitoring, and ART preparatory.
Columbia University
Other
Multi-level Determinants of Late ART Initiation in Sub-Saharan Africa (LSTART Study): A Cross-sectional Qualitative Situation Analysis at 4 HIV Care and Treatment Clinics in Ethiopia
Acronym: LSTART
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02043769
Acquired Immune Deficiency Syndrome (AIDS), Acquired Immunodeficiency Syndrome
East London, Amathole, South Africa
View Trial DetailsNCT02027714
Acquired Immune Deficiency Syndrome (AIDS), Acquired Immunodeficiency Syndrome
Mafeteng, Lesotho
View Trial DetailsNCT02027441
Acquired Immune Deficiency Syndrome (AIDS), Acquired Immunodeficiency Syndrome
Mafeteng, Lesotho
View Trial DetailsNCT01997359
Acquired Immune Deficiency Syndrome (AIDS), Acquired Immunodeficiency Syndrome
Āmbo, Ethiopia
View Trial Details